Alexion Pharmaceuticals IncFind Ratings Reports
ALEXION PHARMACEUTICALS INC's gross profit margin for the second quarter of its fiscal year 2017 is essentially unchanged when compared to the same period a year ago. The company managed to grow both sales and net income at a faster pace than the average competitor in its industry this quarter as compared to the same quarter a year ago. ALEXION PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 2.52 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.
During the same period, stockholders' equity ("net worth") has increased by 8.24% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY17||Q2 FY16|
|Net Sales ($mil)||912.0||753.12|
|Net Income ($mil)||165.0||120.06|
|Balance Sheet||Q2 FY17||Q2 FY16|
|Cash & Equiv. ($mil)||1444.0||1180.05|
|Total Assets ($mil)||13489.0||13029.35|
|Total Debt ($mil)||3248.0||3446.67|
|Profitability||Q2 FY17||Q2 FY16|
|Gross Profit Margin||93.53||94.48|
|Return on Assets||3.86||0.72|
|Return on Equity||5.87||1.15|
|Debt||Q2 FY17||Q2 FY16|
|Share Data||Q2 FY17||Q2 FY16|
|Shares outstanding (mil)||224.0||224.22|
|Div / share||0.0||0.0|
|Book value / share||39.62||36.57|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1878586.0||2969836.0|
BUY. ALEXION PHARMACEUTICALS INC's P/E ratio indicates a significant premium compared to an average of 39.88 for the Biotechnology industry and a significant premium compared to the S&P 500 average of 24.88. Conducting a second comparison, its price-to-book ratio of 3.65 indicates a premium versus the S&P 500 average of 3.10 and a significant discount versus the industry average of 12.14. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.
|ALXN 62.60||Peers 39.88||ALXN 25.66||Peers 27.93|
Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.
ALXN is trading at a significant premium to its peers.
Average. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
ALXN is trading at a valuation on par to its peers.
|ALXN 20.40||Peers 25.67||ALXN 0.29||Peers 0.50|
Average. An average price-to-projected earnings ratio can signify an industry neutral stock price and average future growth expectations.
ALXN is trading at a valuation on par with its peers.
Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
ALXN trades at a significant discount to its peers.
|ALXN 3.65||Peers 12.14||ALXN 450.00||Peers 10.47|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
ALXN is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
ALXN is expected to have an earnings growth rate that significantly exceeds its peers.
|ALXN 9.49||Peers 94.57||ALXN 20.91||Peers 233.22|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
ALXN is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
ALXN significantly trails its peers on the basis of sales growth